This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT01280344 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Helsinn Therapeutics (U.S.), Inc |
| Enrollment | 320 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Gastrointestinal Dysmotility |
| Interventions | Saline Solution for Injection; Ipamorelin |
| Start | Apr 2011 |
| Primary completion | Jun 2013 |
| Study completion | May 2014 |
| Results posted | Not yet |
| Registry last updated | Apr 13, 2017 |
Compounds on this site that cite this trial
What the registry says the trial is about
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Recovery of Gastrointestinal (GI) Function | Up to 10 days |
2 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 16, 2026. See the trial changes feed for what has changed recently.
More trials of Ipamorelin
Research area: Growth hormone axis. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.